CFH5633
Phase 2
NovartisCFH5633 is one of 34 therapeutic programs targeting Eye Disease. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Chantix
PfizerPhase 3
Bayer Aspirin
BayerPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
CF101
CCan-Fite BioPharma
Phase 3
Carboxymethylcellulose
AbbViePhase 3
Refresh Plus
AbbViePhase 3
Cenegermin
DDompé Farmaceutici S.p.A
Phase 3
Csa
ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
Diquafosol Tetrasodium
Merck & Co.Phase 3
REFRESH LIQUIGEL
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for CFH5633. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company